Related Experiment Videos
Protein tyrosine kinase inhibitors: new treatment modalities?
Doriano Fabbro1, David Parkinson, Alex Matter
1Department of Oncology, Novartis Pharma Inc., CH-4002, Basel, Switzerland. doriano.fabbro@pharm.novartis.com
Abstract:
Protein tyrosine kinases (PTKs) have been recognized as attractive cell-signaling targets for drug discovery in the treatment of cancer and other diseases. Most of the PTK inhibitors are small molecules, designed to compete for, or nearby, the ATP-binding site, and are currently in phase I-III clinical trials, mainly for oncological indications. Recent efforts focused on the synthesis of selective PTK inhibitors have generated several promising clinical candidates, which recently culminated in the approval of Gleevec, the first kinase inhibitor registered for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Insights
Protein tyrosine kinases (PTKs) are key targets for cancer drug discovery. Selective PTK inhibitors, like the approved drug Gleevec, show promise in treating various cancers.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Protein tyrosine kinases (PTKs) are crucial in cell signaling pathways.
- Dysregulation of PTKs is implicated in various diseases, particularly cancer.
- PTK inhibitors are a significant area of focus for drug discovery.
Purpose of the Study:
- To highlight the role of PTKs as drug targets.
- To discuss the development and success of PTK inhibitors.
- To emphasize the therapeutic potential of targeting PTKs in cancer treatment.
Main Methods:
- Review of existing literature on PTK inhibitors.
- Analysis of clinical trial data for PTK-targeted therapies.
- Case study of Gleevec as a successful PTK inhibitor.
Main Results:
- PTK inhibitors are predominantly small molecules targeting the ATP-binding site.
- Numerous PTK inhibitors are in various phases of clinical trials for oncological indications.
- The approval of Gleevec marks a significant milestone in kinase inhibitor therapy.
Conclusions:
- Selective PTK inhibitors represent a promising class of drugs for cancer therapy.
- Targeting PTKs offers a viable strategy for developing novel cancer treatments.
- The success of Gleevec validates the therapeutic potential of kinase inhibitors.